Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

FDA puts partial clinical hold on enrollment in LADD trials

Oct. 25, 2016

VBI-1901 shows promising preclinical results

Oct. 24, 2016

Phase III study of denosumab in MM meets primary enpoint

Oct. 24, 2016

Merck & Co.'s KEYNOTE-045 study meets primary endpoint

Oct. 24, 2016

Advaxis begins part B of KEYNOTE-046 trial

Oct. 21, 2016

NBE Therapeutics and SOTIO to develop next-generation ADCs

Oct. 21, 2016

CFDA accepts CStone Pharmaceuticals' IND for anti-PD-L1 monoclonal antibody

Oct. 21, 2016

FDA grants accelerated approval for Lartruvo in soft tissue sarcoma

Oct. 20, 2016

Advanced Proteome Therapeutics acquires option to antibody candidates from University of Toronto

Oct. 20, 2016

FDA approves Tecentriq for metastatic NSCLC

Oct. 19, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 8, 2026.
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
In the clinic for July 6, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Arcus, Genentech, Merck, Myriad, Otsuka, Partner, Revolution, Treos.